In early 2007, BioRexis Pharmaceutical Corporation was acquired by Pfizer. Working in the biopharmaceutical space, the firm had offered protein and peptide drugs with pharmacology and Trans-bodies to replace conventional monoclonal antibodies. The companyÂ's products had included peptide fusion - used for the treatment of type 2 diabetes. Also provided were biopharmaceutical products for longer-acting interferon and an erythropoietin receptor agonist. Addressing problems typical in the biopharmaceuticals space - peptides having a very short half-life, requiring both high and frequent dosing; unwanted side effects from high peak levels can limit therapeutic benefit, and frequent trough low levels may narrow application of the particular product; and among high dosing per patient placing a further burden on already limited manufacturing capacity, driving up the cost of treatment, as in the case of monoclonal antibodies and other high-priced biopharmaceuticals. BioRexis sought to solve theset ypes of problem through a new approach of protein engineering. The goal had been to enable cost-efficient production of high value proprietary biopharmaceuticals that provide longer lasting therapeutic benefit and greater safety.
